Triple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine)
PreclinicalSmall molecule
Triple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine) is one of 25 small molecule programs targeting Hypertension. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
Aceon
Institut de Recherches Internationales ServierPreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Salbutamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details